Dashenlin Pharmaceutical Group Co., Ltd. Class ASSE: 603233

"DaShenLin Pharmaceutical Group Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing

Sep 22, 2026 · Issued by Dashenlin Pharmaceutical Group Co., Ltd. Class A via Shanghai Stock Exchange

Announcement on Convening the 2026 Semi-annual Performance Briefing

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Dashenlin Pharmaceutical Group Co., Ltd. Class A

"DaShenLin Pharmaceutical Group Co., Ltd."First Indicative Announcement on Maturity Redemption and Delisting of "DaShenLin Convertible Bonds"Sep 16
"DaShenLin Pharmaceutical Group Co., Ltd."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026Sep 12
"DaShenLin Pharmaceutical Group Co., Ltd."Notice on Convening the 2nd Extraordinary General Meeting in 2026Aug 25
"DaShenLin Pharmaceutical Group Co., Ltd."Announcement on Reply to the Inquiry Letter on the Company's 2025 Annual ReportJul 21

All Dashenlin Pharmaceutical Group Co., Ltd. Class A news releases